Oncoinvent

Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across a variety of solid cancers. Its lead candidate, Radspherin, is an alpha-emitting radionuclide therapy designed for the treatment of metastatic cancers in body cavities. Radspherin consists of an alpha radiating micro particle suspension that is instilled in the targeted body cavity, allowing local radiopharmaceutical therapy without systemic administration, thereby avoiding exposing healthy tissue to radiation and associated side effects.

In clinical trials, Radspherin has demonstrated strong anticancer activity and excellent safety profiles. In the ongoing Phase 1/2a trials in peritoneal carcinomatosis from colorectal cancer, all dose levels up to the recommended dose of seven MBq have been well tolerated, with only 2.6% of adverse events considered related to Radspherin, all grades 1-2. Notably, none of the 12 patients receiving the seven MBq dose experienced peritoneal recurrences at 18 months. Similarly, in the Phase 1 trial for recurrent ovarian cancer, Radspherin was well tolerated with no dose-limiting toxicity observed.

Oncoinvent has obtained FDA clearance for two Phase 2 billion trials evaluating Radspherin in peritoneal carcinomatosis from colorectal and ovarian cancers, with both studies planned to commence in Q2 2024. The company leverages internal manufacturing capabilities to enable clinical supply of radioisotopes for advancing its alpha-emitting radiopharmaceutical pipeline. In April 2024, Oncoinvent raised NOK 71 million in a private placement to fund further clinical development.